SCYNEXIS (SCYX) Q3 2025 earnings summary

Executive summary

• Resolved a dispute with GSK, resulting in a $24.8M one-time payment and termination of the Phase 3 MARIO study; future milestones and royalties for BREXAFEMME remain intact, with GSK planning a relaunch in 2026.

• Focused on developing novel antifungal agents, with ibrexafungerp (BREXAFEMME) approved for VVC and rVVC, and SCY-247 advancing in clinical trials with positive Phase 1 data.

• GSK's relaunch of BREXAFEMMEⓇ could yield up to $146M in annual net sales milestones and royalties.

• Ended Q3 2025 with $37.9M in cash, cash equivalents, and investments; post-GSK payment, cash runway extends beyond two years.

Financial highlights

• License agreement revenue was $0.3M for Q3 2025, down 49% year-over-year; nine-month revenue was $2.0M, down 29%.

• Net loss for Q3 2025 was $8.6M ($0.17 per share), compared to $2.8M ($0.06 per share) in Q3 2024; nine-month net loss was $20.9M, up from $16.9M year-over-year.

• Research and development expenses decreased 33% to $5.5M in Q3 2025; selling, general, and administrative expenses rose 13% to $3.3M.

• Cash, cash equivalents, and investments totaled $37.9M as of September 30, 2025, down from $75.1M at year-end 2024.

Outlook and guidance

• Capital resources are expected to fund operations for at least 12 months, with cash runway exceeding two years post-GSK payment; additional funding will be needed for continued R&D and operations.

• SCY-247 IV Phase 1 and proof-of-concept Phase 2 studies are planned for 2026, targeting invasive candidiasis and prevention of invasive fungal diseases.

• Exploring non-dilutive funding to support SCY-247 development.